免疫疗法作为晚期和复发性子宫内膜癌的治疗策略：III期免疫疗法临床试验综述
Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials.
作者信息
Eskander Ramez N, Powell Matthew A
机构信息
Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of California San Diego Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA.
出版信息
Ther Adv Med Oncol. 2021 Mar 16;13:17588359211001199. doi: 10.1177/17588359211001199. eCollection 2021.
Abstract
The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.
摘要
晚期、转移性或复发性子宫内膜癌的治疗在临床上仍然是一个难题。尽管卡铂和紫杉醇联合使用是一种有效的标准治疗方案，但其他策略也显示出了前景，尤其是在生物标志物选择的人群中。为了改善肿瘤治疗效果，研究人员正在探索新型免疫疗法组合。在这篇综述中，我们讨论了晚期或复发性子宫内膜癌患者当前III期免疫肿瘤学临床试验的临床原理和设计。
相似文献
1
Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials.
Ther Adv Med Oncol. 2021 Mar 16;13:17588359211001199. doi: 10.1177/17588359211001199. eCollection 2021.
2
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14.
3
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.
Oncologist. 2016 Oct;21(10):1250-1259. doi: 10.1634/theoncologist.2016-0062. Epub 2016 Jul 13.
4
PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
BMC Cancer. 2023 Nov 29;23(1):1166. doi: 10.1186/s12885-023-11654-z.
5
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD012160. doi: 10.1002/14651858.CD012160.pub2.
6
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19.
7
Immuno-Oncology for Gynecologic Malignancies.
Adv Exp Med Biol. 2021;1342:193-232. doi: 10.1007/978-3-030-79308-1_6.
8
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005413.
9
Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):396-412. doi: 10.1016/j.ijrobp.2020.09.016. Epub 2020 Sep 15.
10
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
Gynecol Oncol. 2022 Aug;166(2):317-325. doi: 10.1016/j.ygyno.2022.06.011. Epub 2022 Jun 22.
引用本文的文献
1
Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.
Cancers (Basel). 2024 Nov 22;16(23):3918. doi: 10.3390/cancers16233918.
2
A comprehensive analysis of CEBPA on prognosis and function in uterine corpus endometrial carcinoma.
Sci Rep. 2024 Oct 10;14(1):23773. doi: 10.1038/s41598-024-74242-6.
3
Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe.
Future Oncol. 2024;20(34):2637-2645. doi: 10.1080/14796694.2024.2379233. Epub 2024 Aug 9.
4
Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.
Arch Gynecol Obstet. 2024 Jun;309(6):2833-2841. doi: 10.1007/s00404-024-07504-3. Epub 2024 Apr 18.
5
Loss of NLRP3 reduces oxidative stress and polarizes intratumor macrophages to attenuate immune attack on endometrial cancer.
Front Immunol. 2023 Apr 3;14:1165602. doi: 10.3389/fimmu.2023.1165602. eCollection 2023.
6
PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2022 Aug 13;14(16):3911. doi: 10.3390/cancers14163911.
7
Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.
Gynecol Oncol Rep. 2022 Jun 17;42:101026. doi: 10.1016/j.gore.2022.101026. eCollection 2022 Aug.
8
Polymeric Systems for Cancer Immunotherapy: A Review.
Front Immunol. 2022 Feb 22;13:826876. doi: 10.3389/fimmu.2022.826876. eCollection 2022.
本文引用的文献
1
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19.
2
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
Gynecol Oncol. 2021 Mar;160(3):777-785. doi: 10.1016/j.ygyno.2020.12.010. Epub 2021 Feb 6.
3
Cancer Statistics, 2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
4
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
J Clin Oncol. 2020 Nov 20;38(33):3841-3850. doi: 10.1200/JCO.20.01076. Epub 2020 Sep 29.
5
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29.
6
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
7
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Gynecol Oncol. 2019 Dec;155(3):406-412. doi: 10.1016/j.ygyno.2019.10.013. Epub 2019 Oct 31.
8
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
J Clin Oncol. 2019 Oct 20;37(30):2786-2794. doi: 10.1200/JCO.19.01021. Epub 2019 Aug 28.
9
The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer.
Cancers Head Neck. 2016 Aug 10;1:8. doi: 10.1186/s41199-016-0009-6. eCollection 2016.
10
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
Zotero 插件